Combination Vaccines

2022 ◽  
Author(s):  
Alejandra Esteves-Jaramillo ◽  
Heinz-Josef Schmitt
Keyword(s):  
Pneumococcal Vaccines ◽  
Vaccination Programs ◽  
Medical Visits ◽  
Trivalent Influenza Vaccine ◽  
Combination Vaccines ◽  
Immunological Interactions ◽  
Physical Interactions ◽  
The Individual ◽  
Pediatric Vaccination ◽  
New Vaccines

Combination vaccines have been around since 1945 (trivalent influenza vaccine) and they combine either different serotypes of one microorganism (e.g., influenza or pneumococcal vaccines) or different microorganisms (e.g., DTP combinations). Potential chemical and physical interactions, unpredictable immunological interactions, and in one instance: increased AE, increasing likelihood of production failures, and reduced flexibility of a vaccination program are challenges for developing combination vaccines. With an increasing number of new vaccines for protecting the very young, DTaP- and DTwP-based combinations have become the cornerstone of pediatric vaccination programs around the globe since the mid-1990s. Live vaccine combinations include MR, MMR, and MMRV combinations as well as (trivalent) OPV. Combination vaccines for travelers include HAV-HBV combination and HAV-Ty vaccines. Dozens of diverse combination vaccine products are licensed today around the globe, some of them only in single countries to cover specific local needs. Combination vaccines have been shown to result in increased acceptance, completion and compliance with vaccination programs; in addition, they offer simplified logistics, reduce administration errors, reduce the number of medical visits and cost for the individual as well as for society, among other benefits.

Small talk as work talk: Enacting the patient-centered approach in nurse-practitioner-patient visits

2018 ◽  
Vol 14 (2) ◽  
pp. 97-107 ◽  
Author(s):  
Staci Defibaugh
Keyword(s):  
Nurse Practitioners ◽  
Nurse Practitioner ◽  
Medical Visit ◽  
Patient Centered ◽  
Small Talk ◽  
Medical Visits ◽  
Relational Work ◽  
The Us ◽  
The Individual ◽  
Patient Relationships

Small talk in medical visits has received ample attention; however, small talk that occurs at the close of a medical visit has not been explored. Small talk, with its focus on relational work, is an important aspect of medical care, particularly so considering the current focus in the US on the patient-centered approach and the desire to construct positive provider– patient relationships, which have been shown to contribute to higher patient satisfaction and better health outcomes. Therefore, even small talk that is unrelated to the transactional aspect of the medical visit in fact serves an important function. In this article, I analyze small talk exchanges between nurse practitioners (NPs) and their patients which occur after the transactional work of the visit is completed. I focus on two exchanges which highlight different interactional goals. I argue that these examples illustrate a willingness on the part of all participants to extend the visit solely for the purpose of constructing positive provider–patient relationships. Furthermore, because exchanges occur after the ‘work’ of the visit has been completed, they have the potential to construct positive relationships that extend beyond the individual visit.

Immunizations and vaccines: a decade of successes and reversals, and a call for ‘vaccine diplomacy’

2019 ◽  
Vol 11 (5) ◽  
pp. 331-333 ◽  
Author(s):  
Peter J Hotez
Keyword(s):  
Respiratory Virus ◽  
Neglected Tropical Diseases ◽  
Tropical Diseases ◽  
Virus Infections ◽  
Vaccination Programs ◽  
Vaccine Preventable Diseases ◽  
Health Gains ◽  
Potential Development ◽  
Respiratory Virus Infections ◽  
New Vaccines

Abstract Over the last decade we have seen extraordinary public health gains due to expansions in global vaccination programs led by United Nations (UN) agencies, including Gavi, the Vaccine Alliance, UNICEF and the WHO. These initiatives have reduced childhood deaths from measles, tetanus and other vaccine-preventable diseases by almost one half. There is additional excitement over the potential development and introduction of new vaccines to prevent highly lethal respiratory virus infections, as well as tuberculosis, malaria, HIV/AIDS and several neglected tropical diseases. However, these successes are under threat due to political instability, conflict and an accelerating antivaccine movement. New initiatives in vaccine diplomacy will be required to combat these challenges.

scholarly journals 2716. Persistence of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Serotypes in Invasive Pneumococcal Disease in Adults in Southern Ontario Canada Despite Routine Pediatric Vaccination

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S955-S956
Author(s):  
Allison McGeer ◽  
Agron Plevneshi ◽  
Karen Green ◽  
Brenda Coleman ◽  
Sarah Nayani ◽  
...  
Keyword(s):  
Invasive Pneumococcal Disease ◽  
Pneumococcal Disease ◽  
Medical Information ◽  
Herd Immunity ◽  
Case Fatality ◽  
Population Data ◽  
Vaccination Programs ◽  
Significant Difference ◽  
Statistics Canada ◽  
Pediatric Vaccination

Abstract Background In Ontario, Canada, PCV13 is covered for immunocompromised (IC) adults over 50y. PCV13 programs are thought not to be cost-effective in other adults because it is assumed that herd immunity from pediatric vaccination programs (PCV7 since 2005; PCV13 since 2010) will reduce PCV13 disease burden dramatically in adults. We analyzed data from the Toronto Invasive Bacterial Diseases Network (TIBDN) to ask whether PCV13-type invasive pneumococcal disease (IPD) in adults persists in our population. Methods TIBDN performs population-based surveillance for IPD in Toronto+Peel Region, Ontario (pop4.1M). All microbiology laboratories receiving specimens from residents report cases of IPD and submit isolates to a central study lab for serotyping; annual audits are conducted. Demographic, medical and vaccination information are obtained from patients, families and physicians. Population data are from Statistics Canada. Results Since 1995, 10,365 episodes of IPD have been identified; detailed medical information was available for 9,801 (95%) and serotyping for 9411 (91%). Among 8658 adult cases, 4,273 (49%) were in those aged 15–64 years, and 4,285 (51%) in those aged >645 years. The most common diagnoses were pneumonia (5,978/8,025, 74%) and bacteremia without focus (1,030, 13%); 470 (4.6%) cases had meningitis; the case fatality rate (CFR) was 21%. The incidence of disease due to STs in PCV13 in adults declined from 7.0/100,000/year 2001 to 2.9/100,000/year in 2015–2018 and was stable from 2015–2018 (Figure 1). The incidence was > 5/100,000/year in non-IC patients over 65 years, and younger patients with cancer and kidney disease (Figure 2). In IPD from 2015 to 2018, adult patients with PCV13 ST disease were younger (median age 64 years vs. 67 years, P = .03) than other patients; there was no significant difference in the proportion with at least one underlying chronic condition (253, 69% PCV13ST, vs. 541,74% other ST, P = 0.08), or in CFR (59, 16% PCV13 vs. 145, 20% other, P = 0.13). The ST distribution of cases due to PCV13 STs is shown in Figure 3. Conclusion A significant burden of IPD due to PCV13 serotypes persists in adults in our population despite 8 years of routine pediatric PCV13 vaccination. This burden needs to be considered in assessing the value and cost-effectiveness of PCV programs for adults. Disclosures All authors: No reported disclosures.

scholarly journals Herd immunity: In relation to COVID-19

2020 ◽  
Vol 4 (2) ◽  
pp. 049-055
Author(s):  
Anil Batta
Keyword(s):  
Disease Incidence ◽  
Natural Infection ◽  
Herd Immunity ◽  
Immunization Coverage ◽  
Childhood Immunization ◽  
Vaccination Programs ◽  
Community Protection ◽  
The Individual ◽  
Individual Immunity ◽  
Indirect Protection

Herd immunity, also known as indirect protection, community immunity, or community protection, refers to the protection of susceptible individuals against an infection when a sufficiently large proportion of immune individuals exist in a population. In other words, herd immunity is the inability of infected individuals to propagate an epidemic outbreak due to lack of contact with sufficient numbers of susceptible individuals. It stems from the individual immunity that may be gained through natural infection or through vaccination. The term herd immunity was initially introduced more than a century ago. In the latter half of the 20th century, the use of the term became more prevalent with the expansion of immunization programs and the need for describing targets for immunization coverage, discussions on disease eradication, and cost-effectiveness analyses of vaccination programs. Eradication of smallpox and sustained reductions in disease incidence in adults and those who are not vaccinated following routine childhood immunization with conjugated Haemophilusinfluenzae type B and pneumococcal vaccines are successful examples of the effects of vaccine-induced herd immunity.

scholarly journals Development of nascent focal adhesions in spreading cells

2020 ◽  
Author(s):  
Neil Ibata ◽  
Eugene M. Terentjev
Keyword(s):  
Focal Adhesions ◽  
Cell Spreading ◽  
Angular Frequency ◽  
Ginzburg Landau ◽  
Spatial Modes ◽  
Characteristic Wavelength ◽  
Physical Interactions ◽  
The Individual ◽  
Computer Simulation Studies ◽  
Dense Aggregation

AbstractCell spreading provides one of the simplest configurations in which eukaryotic cells develop angular symmetry-breaking assemblies of mechanosensing and mechanotransducive organelles in preparation for cell differentiation and movement. By identifying the edge of the cell-ECM adhesion area as having an important role in mechanosensor complex aggregation, we consider the spatial patterns arising on this edge, within a 1D lattice model of the nearest-neighbour interaction between individual integrin-mediated mechanosensors. We obtain the Ginzburg-Landau free energy for this model and analyse the spectrum of spatial modes as the cell spreads and increases the contact area. We test the plausibility of our model by comparing its predictions for the azimuthal angular frequency of aggregation of mechanosensors into nascent focal adhesions (FAs) to observations of the paxillin distribution in spreading fibroblasts.STATEMENT OF SIGNIFICANCEThe topic of cell adhesion on substrates is very active, with numerous theoretical, experimental and computer simulation studies probing the mechanisms and signalling pathways of cell response to interacting with substrate. Integrin-based adhesion complexes are known to be the individual units of this process, and their dense aggregation into focal adhesions leads to cells developing asymmetry, polarity, and eventually - locomotion. Here we develop a theoretical model that suggests that physical interactions between individual adhesion complexes is the factor that defines the initial breaking of symmetry of the cell spreading on substrate, and predicts the characteristic wavelength of modulation above the critical size of adhesion area.

scholarly journals Proteomic technologies in the development of new vaccines based on serotype-non-specific protein antigens of Streptococcus pneumoniae

2019 ◽  
Vol 100 (4) ◽  
pp. 680-688
Author(s):  
Yu A Tyuri ◽  
A Z Zaripova ◽  
G Sh Isaeva ◽  
I G Mustafin ◽  
L T Bayazitova
Keyword(s):  
Full Range ◽  
Risk Groups ◽  
Specific Protein ◽  
Production Costs ◽  
New Combination ◽  
Protein Antigens ◽  
Pneumococcal Infections ◽  
Iga1 Protease ◽  
Combination Vaccines ◽  
New Vaccines

The review presents a modern strategy to improve the means of vaccine prevention of streptococcal infections aimed at finding and developing new vaccines for immunization of people belonging to risk groups. It should be noted that pneumococci (S. pneumoniae) are members of gram-positive bacteria (diplococci) and become the main cause of various nosological forms of human infectious diseases (such as pneumonia, otitis media, sinusitis, bacteremia and meningitis). Existing pneumococcal vaccines (conjugate and polysaccharide) have some important limitations, for example, serotype dependence, loss of effectiveness due to a change in the serotype landscape, insufficient protective effect from non-invasive forms of pneumococcal infections and high production costs associated with the development of these products. The main part of the review presents the most important research papers that used modern proteomic technologies in the study of the S. pneumoniae proteomic profile. These works allow us to evaluate at the molecular level the importance of bacterial proteins as candidates for creating new combination vaccines that can effectively protect against the full range of pneumococcal serotypes circulating in the human population. So, in particular, the data are provided on the new methodology for the analysis of the proteome of extracellular S. pneumoniae bacterial microvesicles to identify immunoreactive protein antigens, potential candidates for inclusion into vaccines. As a result of these studies, 15 immunoreactive proteins were discovered, 7 of which are cytosolic and 8 proteins are bound to the cell surface (MalX, ABC transporter or substrate binding transport protein, AmiA, AliA, LytC, IgA1 protease, PspA and the putative precursor of β-galactosidase). These are possible candidates for developing combination vaccines. Additionally, the review presents data on the role of significant virulence factors of the protein nature of S. pneumoniae strains in nasopharyngeal colonization, increased infectivity, as well as on overcoming reactions of the host's immune response.

COMPLEXCITY: MODELING URBAN MOBILITY

2007 ◽  
Vol 10 (supp02) ◽  
pp. 255-270 ◽  
Author(s):  
ARMANDO BAZZANI ◽  
SANDRO RAMBALDI ◽  
BRUNO GIORGINI ◽  
GIORGIO TURCHETTI
Keyword(s):  
Current Status ◽  
Urban Mobility ◽  
Agent Based ◽  
Cognitive Dynamics ◽  
Vehicle Trajectories ◽  
Single Vehicle ◽  
Private Car ◽  
Physical Interactions ◽  
Individual Citizen ◽  
The Individual

We consider the problem of modeling urban mobility using the complex systems key of lecture. We discuss the properties of the Auto-mobilis model, a virtual simulator for private car mobility based on the individual citizen propensities and the existence of "chronotopoi", which are the primary causes of citizens' mobility requests. Auto-mobilis is a microscopic agent-based model that takes into account both the physical interactions and the cognitive dynamics. We present the current status of the project and discuss the applications to real situations. The model assumptions are justified by a comparison with GPS observational data on single vehicle trajectories.

scholarly journals New vaccination protocols for the dog and cat: the challenge of today for a better and safer prevention

2017 ◽  
Vol 62 (3) ◽  
pp. 257
Author(s):  
M. E. MYLONAKIS (Μ.Ε. ΜΥΛΩΝΑΚΗΣ) ◽  
A. F. KOUTINAS (Α.Φ. ΚΟΥΤΙΝΑΣ) ◽  
M. SARIDOMICHELAKIS (Μ. ΣΑΡΙΔΟΜΙΧΕΛΑΚΗΣ) ◽  
C. K. KOUTINAS (Χ.Κ. ΚΟΥΤΙΝΑΣ) ◽  
N. SOUBASIS (Ν. ΣΟΥΜΠΑΣΗΣ) ◽  
...  
Keyword(s):  
Adverse Reactions ◽  
Scientific Evidence ◽  
Herd Immunity ◽  
Care Program ◽  
Preventive Health Care ◽  
Time Interval ◽  
Vaccination Programs ◽  
One Year ◽  
The One ◽  
The Individual

Vaccinations are an integral part of a comprehensive preventive health care program targeting to minimize the incidence of major canine and feline infectious diseases. Currently, vaccination practices are re-evaluated globally towards a twofold objective: to strengthen "herd immunity", which depends on the percentage of vaccinated animals in a population, and to reduce the "vaccine load" per animal in order to minimize the vaccine-associated adverse reactions. To this end, the updated canine and feline vaccination guidelines, encourage the vaccination of as many animals as possible, while at the same time classify the vaccines into core, non-core and not recommended. Core vaccines should be administered, if possible, to every dog and cat.Canine parvovirus-2, canine adenovirus-2, canine distemper virus, feline parvovirus, feline calicivirus/herpesvirus-1 and rabies vaccines fall into this category. Non-core vaccines are selectively given to dogs and cats after assessing the risk/benefit ratio. There are also vaccines for which there is currently no sufficient scientific evidence to justify their use. Importantly, after the one-year booster inoculation that follows the completion of the initial puppy/kitten vaccination series, core vaccines should be given no more frequently than every three years, as the duration of the protective immunity far exceeds this time interval. This review focuses on the updated canine and feline vaccination guidelines pertaining to the individual animal as well as to those living in groups. Important questions related to vaccination programs and to relevant adverse reactions are also answered. An effort has been made to align these guidelines according to what is considered a "norm" among the small amimal practitioners in Greece.

Sign in / Sign up

Export Citation Format

Share Document